144481-98-1

Product Details:

CasNo： 144481-98-1

Molecular Formula： C25H40ClN3O8

Purity： 99%

Synonyms: [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl3-[4-[(2S)-2-hydroxy-3-[2-(morpholine-4-carbonylamino)ethylamino]propoxy]phenyl]propanoate hydrochloride; Benzenepropanoic acid,4-(2-hydroxy-3-((2-((4-morpholinylcarbonyl)amino)ethyl)amino)propoxy)-,(2,2-dimethyl-1,3-dioxolan-4-yl)methylester,(S-(R*,R*))-,hydrochloride; -2,2-Dimethyl-1,3-dioxolan-4-yl); -2-hydroxy-3-((2-(morpholine-4-carboxamido); methyl 3-(4-((S); propanoate hydrochloride

Melting point: 125.4 ºC

Solubility: DMSO (Slightly), Ethanol (Slightly, Sonicated)

Form: Solid
Color: White to off-white

Description:

Landiolol hydrochloride was launched in Japan by Ono for the treatment of intraoperative tachyarrhythmia. It improves tachyarrhythmia by selectively blocking β1 receptors located mainly in the heart and by inhibiting the action of catecholamine.

Uses:

Landiolol is an ultra-short acting beta blocker that is used to treat patients with cardiac arrhythmias and is also used to treat tachycardia during anasthesia.

Definition:

Landiolol hydrochloride is a member of morpholines.

Clinical Use:

Landiolol hydrochloride, a highly cardio-selective beta-1 blocker with an ultra-short-acting half-life of 4 minutes. β-blockers is useful in preventing refractory and urgent fatal arrhythmia and tachycardia in chronic phase.Recently, Landiolol was originally approved by Japan for treatment of intraoperative tachyarrhythmias and was later approved for tachycardia atrial fibrillation (AF) and atrial flutter (AFL) during left ventricular (LV) dysfunction in November 2013. More recently, landiolol expanded its utility into usage for fatal arrhythmia requiring emergency treatment in 20196 and is fast becoming a reliable therapeutic choice for management of arrhythmia in acute phase.